.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,461,586

« Back to Dashboard

Details for Patent: 6,461,586

Title: Method of magnetic resonance focused surgical and therapeutic ultrasound
Abstract:A novel method for the controlled delivery of therapeutic compounds to a region of a patient, using magnetic resonance focused therapeutic ultrasound, is disclosed.
Inventor(s): Unger; Evan C. (Tucson, AZ)
Assignee: Imarx Therapeutics, Inc. (Tucson, AZ)
Filing Date:Jul 10, 2000
Application Number:09/613,210
Claims:1. A method for the controlled delivery of therapeutic compounds to a region of a patient using magnetic resonance focused therapeutic ultrasound comprising: administering a contrast medium for magnetic resonance imaging comprising gas filled vesicles which comprise a therapeutic compound to a patient; scanning said patient with magnetic resonance imaging using said contrast medium to determine the presence of the vesicles in the region; and applying ultrasound to said region to rupture said vesicles to release the therapeutic compound in the region.

2. A method of claim 1 wherein said application of ultrasound is simultaneous with a second scanning step whereby said patient is scanned with magnetic resonance imaging.

3. A method of claim 1 wherein said application of ultrasound is followed by a second scanning step whereby said patient is scanned with magnetic resonance imaging.

4. A method of claim 1 wherein said region of a patient is selected from the group consisting of: cardiovascular region; gastrointestinal region; intranasal tract; auditory canal; intraocular region; intraperitoneal region; kidneys; urethra; genitourinary tract, brain, spine, pulmonary region, and soft tissues.

5. A method of claim 1 wherein said gas-filled vesicles comprise a targeting agent.

6. A method of claim 1 wherein said therapeutic compound is selected from the group consisting of an oligonucleotide sequence, an antisense sequence, an antibody, and a chemotherapeutic agent.

7. A method of claim 1 wherein said gas filled vesicles are administered intravenously.

8. A method of claim 1 wherein said gas is selected from the group consisting of air, nitrogen, carbon dioxide, oxygen, fluorine, helium, argon, xenon, neon, and combinations thereof.

9. A method of claim 1 wherein said gas comprises a fluorinated gas.

10. A method of claim 9 wherein the fluorinated gas comprises a perfluorocarbon or sulfur hexafluoride.

11. A method of claim 10 wherein the perfluorocarbon gas is selected from the group consisting of perfluoropropane, perfluorobutane, perfluorocyclobutane, perfluoromethane, perfluoroethane, perfluorohexane, and perfluoropentane.

12. A method of claim 1 wherein said gas comprises .sup.17 O.

13. A method of claim 1 wherein said contrast medium further comprises a paramagnetic agent or a superparamagnetic agent.

14. A method of claim 13 wherein the contrast medium comprises a paramagnetic agent.

15. A method of claim 14 wherein the paramagnetic agent comprises a paramagnetic ion selected from the group consisting of transition, lanthanide and actinide elements.

16. A method of claim 15 wherein the paramagnetic ion is selected from the group consisting of Gd(III), Mn(II), Cu(II), Cr(III), Fe(II), Fe(III), Co(II), Er(II), Ni(II), Eu(III) and Dy(III).

17. A method of claim 16 wherein the paramagnetic ion is Mn(II).

18. A method of claim 14 wherein the paramagnetic agent comprises a nitroxide.

19. A method of claim 13 wherein the contrast medium comprises a superparamagnetic agent.

20. A method of claim 19 wherein the superparamagnetic agent comprises a metal oxide or metal sulfide.

21. A method of claim 20 wherein the superparamagnetic agent comprises a metal oxide wherein the metal is iron.

22. A method of claim 20 wherein the superparamagnetic agent is selected from the group consisting of ferritin, iron, magnetic iron oxide, .gamma.-Fe.sub.2 O.sub.3, manganese ferrite, cobalt ferrite and nickel ferrite.

23. A method of claim 1 wherein said gas filled vesicles comprise .sup.19 F and said magnetic resonance imaging is nuclear magnetic resonance.

24. A method of claim 1 wherein said gas filled vesicles are administered interstitially.

25. A method of claim 1 wherein said gas is selected from the group consisting of hyperpolarized xenon, hyperpolarized argon, hyperpolarized helium, and hyperpolarized neon.

26. A method of claim 1 wherein said vesicles comprise liposomes.

27. A method of claim 26 wherein said liposomes comprise crosslinked or polymerized liposomes.

28. A method of claim 26 wherein said liposomes comprise polymerized lipids.

29. A method of claim 26 wherein said liposomes further comprise polyethylene glycol.

30. A method of claim 1 wherein said vesicles comprise a monolayer.

31. A method of claim 30, wherein said monolayer comprises a phospholipid.

32. A method of claim 31, wherein said gas comprises perfluoropropane, perfluorobutane, perfluoropentane, perfluorohexane, or sulfur hexafluoride.

33. A method of claim 31, wherein said monolayer comprises a phospholipid and said gas comprises perfluoropentane.

34. A method of claim 31, wherein said monolayer comprises a phospholipid and said gas comprises sulfur hexafluoride.

35. A method of claim 31, wherein said monolayer comprises a phospholipid and said gas comprises perfluoropropane.

36. A method of claim 1, wherein said vesicles comprise a polymer.

37. A method of claim 36, wherein said polymer comprises an acrylate.

38. A method of claim 37, wherein said gas comprises air.

39. A method of claim 36, wherein said polymer comprises a methacrylate.

40. A method of claim 39, wherein said gas comprises air.

41. A method of claim 36, wherein said polymer comprises a cyanoacrylate.

42. A method of claim 41 wherein said gas comprises air.

43. A method of claim 1, wherein said vesicles comprise a polysaccharide.

44. A method of claim 43, wherein said polysaccharide comprises galactose.

45. A method of claim 44, wherein said gas is nitrogen.

46. A method of claim 1, wherein said vesicles comprise a surfactant.

47. A method of claim 46, wherein said gas comprises perfluoropropane, perfluorobutane, perfluoropentane, perfluorohexane, sulfur hexafluoride, nitrogen, or mixtures thereof.

48. A method of claim 47, wherein said gas comprises a mixture of perfluoropropane and nitrogen.

49. A method of claim 48, wherein said gas comprises a mixture of perfluorohexane and nitrogen.

50. A method of claim 46, wherein said vesicles have been rehydrated from lyophilized vesicles.

51. A method of claim 1, wherein said therapeutic compound comprises a bioactive agent.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc